EQS-News: APONTIS PHARMA publishes results for the first quarter of 2025 and confirms forecast for 2025

APONTIS PHARMA publishes results for the first quarter of 2025 and confirms forecast for 2025
 

• Group sales rise to EUR 12.9 million in Q1 2025 (3M 2024: EUR 10.0 million)
• Single Pill combinations grew strongly overall by EUR 0.6 million. The portfolio more than compensated for the tender-related decline of EUR 1.0 million at Tonotec.
• Further improvement in EBITDA to EUR 1.3 million (3M 2024: EUR 1.0 million)
• Net income rises by 93.0% to EUR 0.7 million (3M 2024: EUR 0.4 million)
• Forecast for financial year 2025 confirmed

Monheim am Rhein, 15 May 2025. APONTIS PHARMA AG (Ticker APPH / ISIN DE000A3CMGM5), a leading pharmaceutical company for Single Pill combinations in Germany, continued its growth in the first quarter of 2025, increasing sales by EUR 2.9 million to EUR 12.9 million (3M 2024: EUR 10.0 million). In conjunction with the significantly reduced cost base, profitability also improved further.

The increase in consolidated sales in the first quarter of 2025 was due, among other things, to higher sales of Single Pill combinations, which rose from EUR 8.8 million in the first quarter of 2024 to EUR 9.4 million in the reporting period. Here, the significant increase in sales of the remaining Single Pill portfolio more than offset the tender-related decline in sales of the product Tonotec of EUR 1.0 million. The cooperation business developed strongly, more than tripling to EUR 3.3 million in the first quarter of 2025 (3M 2024: EUR 0.9 million). This was particularly influenced by the exclusive cooperation agreement for marketing and sales support for two asthma drugs from Novartis, which started in April 2024.

Earnings before interest, taxes, depreciation and amortisation (EBITDA) improved to EUR 1.3 million in the first quarter of 2025, mainly due to higher revenues and lower costs. In the same period of the previous year, EBITDA amounted to EUR 1.0 million.

“In the first quarter of 2025, APONTIS PHARMA continued the growth of previous quarters. The reorganisation of the company, which we implemented in March last year, is proving successful. Both the new go-to-market approach and the reduced cost base are having a positive impact on all items in our income statement,” says Bruno Wohlschlegel, CEO of APONTIS PHARMA.

Total assets increased to EUR 46.8 million as of 31 March 2025, compared to EUR 44.4 million as of 31 December 2024. The equity ratio decreased slightly to 67.8% (31 December 2024: 69.9%), confirming the company's solid financial position. The positive business development in the first quarter of 2025 also led to a significant improvement in cash flow from operating activities, which increased to EUR 1.5 million (3M 2024: cash outflow of EUR -2.8 million).

Group figures (unaudited)

in EUR million	3M 2025	3M 2024	∆
Single Pill revenue	9.4	8.8	0.6
Total sales	12.9	10.0	2.9
EBITDA	1.3	1.0	0.3
EBITDA margin (in %)	10.3%	9.8%	50 bps.
EBIT	1.0	0.5	0.5
EBIT margin (in %)	7.5%	4.5%	300 bps.
Net result	0.7	0.4	0.3
	31 Mar. 2025	31 Dec. 2024
Equity ratio (in %)	67.8%	69.9%	-210 bps.
Net liquidity	15.7	15.5	0.2

Note: The figures for the three-month period are unaudited. Rounding differences may occur.

Squeeze-outs planned under merger law

On 5 March 2025, Zentiva AG submitted a request to APONTIS PHARMA AG pursuant to Section 62 (1) and (5) of the German Merger Act (UmwG) in conjunction with Sections 327a et seq. of the German Stock Corporation Act (AktG), according to which a merger agreement is to be concluded between the company and Zentiva AG and the Annual General Meeting of APONTIS PHARMA is to resolve on the transfer of the shares of the remaining shareholders (minority shareholders) to Zentiva as the main shareholder in return for an appropriate cash compensation (a so-called squeeze-out under merger law).

Zentiva has informed APONTIS PHARMA that, after deducting the number of APONTIS PHARMA's own shares (170,000 shares) in accordance with Section 62 (1) sentence 2 UmwG, it holds approximately 93.83% of the company's share capital. This makes Zentiva the main shareholder of APONTIS PHARMA within the meaning of Section 62 (5) of the German Merger Act (UmwG) in conjunction with Section 327a (1) of the German Stock Corporation Act (AktG).

Zentiva will announce the amount of the appropriate cash compensation that it will grant to the remaining shareholders of the company for the transfer of the shares at a later date. APONTIS PHARMA will announce the date of the general meeting at which a corresponding transfer resolution is to be passed in accordance with the statutory requirements. In addition, Zentiva has proposed entering into negotiations on a merger agreement between Zentiva and APONTIS PHARMA.

Forecast confirmed

In the 2025 financial year, APONTIS PHARMA intends to continue on its growth course and further expand its Single Pill business. This will mainly be achieved through the existing Single Pill portfolio and the effects of the planned new launches in 2025. Business could be dampened by the fact that competitors for Atorimib have won significant tenders from health insurance companies, which will take effect in June 2025. The cooperation business is expected to continue to grow, particularly due to the cooperation agreement entered into with Novartis in April 2024.

Despite the market entry of competitors for Atorimib, APONTIS PHARMA continues to expect sales to increase by 16% to EUR 56.4 million in the 2025 financial year (2024: EUR 48.5 million). The company anticipates EBITDA to rise from EUR 3.5 million to EUR 4.5 million.

Condensed Group Statement of Income (unaudited)

in EUR million	3M 2025	3M 2024	∆
Sales	12.9	10.0	2.9
Other operating income	0.5	0.3	0.2
Cost of materials	-4.8	-3.1	-1.7
Gross profit	8.6	7.2	1.4
Personnel expenses	-3.5	-3.7	0.2
Depreciation and amortization	-0.4	-0.5	0.1
Other operating expenses	-3.8	-2.5	-1.3
Operating result	1.0	0.5	0.5
Financial result	0.0	-0.1	0.1
Result before taxes	1.0	0.4	0.6
Taxes on income and earnings	-0.3	0.0	-0.3
Result after taxes	0.7	0.4	0.3
Other taxes	0.0	0.0	0.0
Net result	0.7	0.4	0.3

Note: The figures for the three-month period are unaudited. Rounding differences may occur.

Condensed Group Statement of Financial Position (unaudited)

in EUR million	31 Mar. 2025	31 Dec. 2024	∆
Assets
Fixed assets	19.4	18.5	0.9
Inventories	6.3	6.5	-0.2
Receivables	2.2	0.8	1.4
Cash on hand and bank balances	15.7	15.5	0.2
Prepaid expenses and deferred charges	1.0	0.7	0.3
Deferred tax assets	2.2	2.4	-0.2
Liabilities
Equity	31.7	31.0	0.7
Difference from capital consolidation	0.5	0.5	0.0
Provisions	7.6	7.8	-0.2
Bank liabilities	0.0	0.0	0.0
Liabilities	7.0	5.1	1.9
Balance sheet total	46.8	44.4	2.4

Note: The figures as of March 31, 2025, are unaudited. Rounding differences may occur.

Condensed Group Statement of Cash Flows

in EUR million	3M 2025	3M 2024	∆
Cash flow from operating activities	1.5	-2.8	4.3
Cash flow from investing activities	-1.2	-0.5	-0.8
Cash flow from financing activities	0	0	0
Net cash flow	0.3	-3.2	3.5

Note: The figures for the three-month period are unaudited. Rounding differences may occur.

About APONTIS PHARMA

APONTIS PHARMA AG is a leading pharmaceutical company specializing in Single Pill combinations in Germany. Single Pills combine two to three generic active ingredients in a single dosage form administered once a day. Single Pill therapies have been scientifically proven to significantly increase adherence and thus improve the treatment prognosis and quality of life of patients while reducing complications, mortality, and treatment costs. Consequently, Single Pill combinations are the preferred treatment option in numerous international treatment guidelines, including in the EU and Germany. APONTIS PHARMA has been developing, marketing and distributing a broad portfolio of single-pill combinations and other medicines since 2013, with a particular focus on cardiovascular diseases such as hypertension, hyperlipidaemia and secondary prevention, as well as asthma. For additional information about APONTIS PHARMA, please visit www.apontis-pharma.de.

APONTIS PHARMA AG

Investor Relations
ir@apontis-pharma.de
T: +49 2173 89 55 4900
F: +49 2173 89 55 1521
Rolf-Schwarz-Schütte-Platz 1
40789 Monheim am Rhein
Germany
apontis-pharma.de

APONTIS PHARMA Press Contact

CROSS ALLIANCE communication GmbH
Sven Pauly
ir@apontis-pharma.de
T: +49 89 125 09 0330